Company Filing History:
1 out of 1,744 
1 out of 10 Years Active: 2013
Title: Marc Bartoli: Innovator in Dysferlinopathy Treatment
Introduction
Marc Bartoli is a notable inventor based in Marseille, France. He has made significant contributions to the field of medical research, particularly in the treatment of dysferlinopathies. His innovative approach focuses on restoring the function of mutated dysferlin, which is crucial for patients suffering from this condition.
Latest Patents
Marc Bartoli holds a patent for "Exon skipping therapy for dysferlinopathies." This invention relates to methods for restoring the function of a mutated dysferlin by preventing the splicing of one or more exons that encode amino acid sequences causing dysferlin dysfunction. Specifically, the splicing of exon 32 is targeted. The patent also outlines a method for treating dysferlinopathy in patients by administering antisense oligonucleotides that are complementary to the necessary nucleic acid sequences for correct splicing.
Career Highlights
Throughout his career, Marc Bartoli has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de la Méditerranée—Aix-Marseille II. His work has been pivotal in advancing the understanding and treatment of genetic disorders.
Collaborations
Marc has collaborated with notable colleagues, including Nicolas Levy and Martin Krahn. Their combined expertise has contributed to the development of innovative therapies in the field of dysferlinopathies.
Conclusion
Marc Bartoli's contributions to medical research, particularly through his patent on exon skipping therapy, highlight his commitment to improving the lives of patients with dysferlinopathies. His work exemplifies the impact of innovation in the medical field.